Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, 3-Part, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lu AG22515 (APB-A1) in Healthy Adult Subjects

NCT05136053 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05136053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05136053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, 3-Part, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lu AG22515 (APB-A1) in Healthy Adult Subjects
Lead sponsor
H. Lundbeck A/S
Phase
Phase 1
Overall status
Completed
Start date
March 18, 2022
Completion date
August 5, 2023
Enrollment
58 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants